Opthea in active talks with funders after second trial fails
The Australian Financial Review03-31
ASX-listed biotech Opthea says it has terminated the second of its two trials of drugs to treat a common eye disease, delivering a near mortal blow to shareholders who had already written down the majority of their investments.
The company said on Monday that a second phase 3 trial “did not meet its primary endpoint” after disappointing investors only last week with the news that a first phase 3 trial had failed.
Loading...
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments